Bottom line
Is IQSM a good fund? The bottom line
IQSM is a managed mid-cap ETF from New York Life Investments.
Its expense ratio is 0.15% — about $15 a year on every $10,000 invested, cheaper than 95% of mid-cap funds we track.
It returned +8.0% over one year (as of Dec 31, 2025, per its prospectus).
With $330 million in net assets and 248 holdings, its largest position is Revolution Medicines Inc (1.3%) and the top 10 make up 9.2% of the portfolio.
What stands out
- Low cost: cheaper than 95% of mid-cap peers
- Broadly diversified (248 holdings)
Updated Nov 19, 2026
What IQSM invests in
The NYLIM Candriam U.S. Mid Cap Equity ETF (the Fund) seeks investment results that correspond (before fees and expenses) generally to the price and yield performance of its underlying index, the NYLIM Candriam U.S. Mid Cap Equity Index (the Underlying Index).
The Fund employs a passive management or indexing investment approach designed to track the performance of the Underlying Index. The Advisor is the index provider for the Underlying Index and Candriam serves as the index consultant to the Advisor for the Underlying Index. In its role as index consultant, Candriam assists the Advisor with the development, calculation and maintenance of the Underlying Index, including the ESG security selection process for the Underlying Index. The Underlying Index is designed to deliver exposure to equity securities of companies meeting environmental, social and corporate governance (ESG) criteria developed by Candriam and weighted using a market-capitalization weighting methodology. The Fund will, under normal circumstances, invest at least 80% of its assets (net assets, plus the amount of any borrowings for investment purposes) in the investments…
From the fund's prospectus (filed Aug 26, 2026).
IQSM performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| IQSM | +8.0% | — | — |
| Mid-Cap median | +7.9% | +8.1% | +9.9% |
Source: Fund prospectus, as of Dec 31, 2025
What IQSM costs
On a $10,000 investment, IQSM's 0.15% expense ratio costs about $15 a year. The prospectus estimates $192 in total costs over 10 years (assuming 5% annual returns). The median mid-cap fund charges 0.88%.
IQSM top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Revolution Medicines Inc RVMD | 1.32% |
| 2 | Twilio Inc TWLO | 1.01% |
| 3 | Nvent Electric Plc NVT | 0.93% |
| 4 | Burlington Stores Inc BURL | 0.93% |
| 5 | US Foods Holding Corp USFD | 0.92% |
| 6 | Okta Inc OKTA | 0.90% |
| 7 | F5 Inc FFIV | 0.88% |
| 8 | Guardant Health Inc GH | 0.83% |
| 9 | Viatris Inc VTRS | 0.78% |
| 10 | Mks Inc MKSI | 0.76% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 9.2% of the fund. See all top 25 holdings and asset mix →